HPLC analyses of the ntla cMOs 8a and 8e and their photolysis reactions. Peak areas for the ntla MO, inhibitor, and cMO oligomers after UV irradiation indicate that 8a and 8e are photocleaved with yields of 74% and 75%, respectively. (C) Representative thermal denaturation curves for the photocleavage products of ntla cMOs 8a and 8e. Figure S2 . Gel-shift analysis of MO/inhibitor exchange with RNA. Intermolecular "staggered" and "blunt" MO/inhibitor duplexes corresponding to ntla cMOs 8a and 8e, respectively, were incubated with complementary 25-base RNA labeled with fluorescein. RNA exchange was allowed to occur for the indicated lengths of time, and the resulting products were then rapidly resolved by polyacrylamide gel electrophoresis. RNA exchange was complete for all MO/inhibitor duplexes within the time frame of each experimental condition. Figure S3 . Activity profiles of heg cMOs of different structures. Schematic representations of heg cMOs 9a (A), 9b (B), 9c (C) and the distribution of phenotypes for each cMO configuration (460 fmol/embryo) are shown. Phenotypes were categorized as either wildtype (WT) or mutant (heart defects resulting in a lack of blood circulation and cardiac edema). 
S8
Scheme S1. cMO assembly through solid-phase synthesis and "click chemistry."
2 Reagents and conditions: (a) MMTrCl, TEA, DCM, 41%; (b) LiAlH 4 , THF, 99%; (c) succinic anhydride, DMAP, pyridine, 49%; (d) amine-functionalized resin, HBTU, HOBt, N-ethylmorpholine, NMP, 63%; (e) HOAc, trifluoroethanol; (f) Fmoc-propargylglycine, HBTU, HOBt, N-ethylmorpholine, NMP; (g) piperidine, DMF; (h) MMTr-6-aminocaproic acid, HBTU, HOBt, N-ethylmorpholine, NMP, 85% over four steps; (i) HOAc, trifluoroethanol; (j) linker-conjugated MO monomer, N-ethylmorpholine, NMP, 67% over four steps; (k) solid-phase synthesis of morpholino oligomer using morpholino monomers; (l) NH 4 OH, 49% from first monomer for oligomer synthesis. Table S1 . Thermodynamic parameters of duplexes generated by ntla cMO photolysis
S9
36.8 ± 1.8 + 0.5 -11.2 ± 0.7 -0.5 8e 41.6 ± 1.4 -4.1 -11.9 ± 0.4 + 0.4 a Dimers of MO and inhibitory MO oligomers generated by photolysis of hairpins with 360-nm light. b Difference in melting temperature between cleaved hairpins and unmodified dimers ( Table 2) . c Binding free energy of the hairpin photolysis products at 28 °C, d Difference in duplex free energy between cleaved hairpins and unmodified dimers ( Table 2) .
S11
Derivation of equations describing non-photoactivated cMO/RNA binding in vitro
S12
Derivation of equations describing photoactivated cMO/RNA binding in vitro
S13
Derivation of equations modeling functional MO/RNA interactions in vivo 173.94, 154.09, 147.47, 138.70, 136.20, 108.96, 107.58, 65.28, 56.57, 56.37, 51.65, 44.66, 36.09, 35.58, 33.86, 33.06, 24.70, 24.64 53, 171.01, 154.59, 153.18, 147.60, 139.35, 131.53, 124.28, 109.01, 108.09, 80.88, 78.57, 78.30, 71.59, 68.34, 66.48, 55.93, 50.35, 34.57, 34.50, 32.76, 29.99, 28.57, 27.33, 25.38, 24.57, 24.16, 23.73, 23.68 
Derivation of equations modeling functional MO/inhibitor interactions in vivo
€ K app MO •INH = [MO][INH] [MO•INH] € K app MO •RNA = [MO][RNA] [MO•RNA] € [MO] t = [MO] + [MO•INH] + [MO•RNA] ≈ [MO] + [MO•INH] € [RNA] t = [RNA] + [MO•RNA] € [INH] t = [INH] +[MO • INH] € [RNA] t = K app MO •RNA [MO•RNA] [MO] + [MO•RNA] € [MO•RNA] [RNA] t = [MO] K app MO •RNA + [MO] € RNA MO,INH Act RNA WT Act = 1− [MO•RNA] [RNA] t = 1− [MO] K app MO •RNA + [MO] = K app MO •RNA K app MO •RNA + [MO] (Eq. 6) € [MO] ≈ [MO] t − [MO•INH] € [INH] t = K app MO •INH [MO•INH] [MO] + [MO•INH] € [MO•INH] = [INH] t [MO] K app MO •INH + [MO] € [MO] ≈ [MO] t − [INH] t [MO] K app MO •INH + [MO] € [MO] 2 + ( K app MO •INH − [MO] t + [INH] t )[MO] − K app MO •INH [MO] t ≈ 0 € [MO] ≈ − ( K app MO •INH − [MO] t + [INH] t ) + ( K app MO •INH − [MO] t + [INH] t ) 2 + 4K app MO •
2,5-Dioxopyrrolidin-1-yl 14-(4,5-dimethoxy-2-nitrophenyl)-17-methyl-5,12,18-trioxo-13-oxa 4,11,17-triazatricos-1-yn-23-oate (2a).
Compound 5a (121 mg, 0.200 mmol) was dissolved in a mixture of MeOH (2 mL), THF (2 mL) and 6 M aq. NaOH (2 mL). The reaction mixture was stirred for 3 h at room temperature. After the reaction solvent was removed in vacuo, the resulting residue was dissolved in EtOAc, washed once with 1 M HCl, and dried over anhydrous Na 2 SO 4 . Solvent was removed in vacuo, and the residue was purified by SiO2 column chromatography (MeOH/EtOAc = 1/9) to yield the carboxylic acid as a light yellow oil (110 mg, 93% 42, 171.10, 154.61, 153.19, 147.60, 139.35, 135.59, 131.53, 109.01, 108.10, 80.89, 78.57, 71.60, 68.36, 55.92, 34.57, 34.37, 33.34, 33.12, 31.57, 28.58, 27.35, 25.38, 24.17, 23.84, 23.78, 23.74 S22 DMNB-conjugated ntla MO inhibitory oligomers (7a-h). Synthetic procedures for the ntla MO inhibitors were analogous to those described for 7e.
MO sequences were: 7a 
DMNB-based ntla cMOs (8a-h).
Synthetic procedures for the ntla cMOs were analogous to those described for 8e. Compounds 8a-h were recovered as yellow solids (5.6-10.5 nmol, 6-10% overall 
Non-cleavable ntla MO hairpins (8a' and 8e'). The functionalized oligomers 7a' and 7e'
(50 nmol) were conjugated with azide-functionalized ntla MO 6 (50 nmol). The synthetic procedures and yields were identical to those of 8a-h. 
8-Bromo-2-formylquinolin-7-yl benzenesulfonate (16).
A mixture of SeO 2 (500 mg, 4.51 mmol) and 1,4-dioxane (10 mL) was heated to over 80 °C. 8-Bromo-2-methylquinolin-7-yl benzenesulfonate (15, 1.70 g, 4.49 mmol) in 1,4-dioxane (5 mL) was added. After stirring at 80 °C for 24 h, the reaction was cooled and vacuum filtered. The filtrate was collected and concentrated to yield a 33, 153.80, 149.08, 146.10, 138.35, 135.82, 135.17, 129.79, 129.66, 128.99, 128.37, 125.61, 119.93, 118.51 
8-Bromo-2-(1-hydroxybut-3-enyl)quinolin-7-yl benzenesulfonate (17).
A mixture of compound 16 (448 mg, 1.14 mmol), indium powder (150 mg, 1.31 mmol) and allyl bromide (160 µL, 1.87 mmol) were stirred in a mixture of 10 mL THF and 10 mL aq. NH 4 Cl for 3 hours. THF was removed in vacuo, and residue was extracted with EtOAc and then dried over anhydrous Na 2 SO 4 .
Solvent was removed in vacuo, and the residue was purified by SiO 2 column chromatography (hexanes/EtOAc = 2/1) to yield 17 as a colorless oil (478 mg, 1.10 mmol, 96%). 1 H NMR (500 MHz, 40, 148.17, 144.08, 137.34, 135.61, 134.86, 133.88, 129.40, 128.67, 128.01, 126.84, 122.47, 119.53, 118.22, 118.12, 72.24, 42 .34. 23-8.16 (m, 1H), 7.99-7.96 (m, 2H), 7.84-7.79 (m, 1H), 7.73-7.68 (m, 2H), 7.62-7.45 (m, 3H), 5.40-5.16 (m, 1H), 4.92-4.85 (m, 1H), 3.78-3.72 (m, 1H), 3.66 (m, 3H), 3.46-3.40 (m, 1H) instructions. The desired product was purified from the reaction mixture by adjusting the solution pH to 11.5 with aq. 1 M NaOH and loading it onto a DNAPac PA-100 ion-exchange HPLC column (Dionex, 9 mm x 250 mm). Aqueous running buffers were A: 0.02 M NaOH, 1% CH 3 CN; B: 0.375 M NaClO 4 in 0.02 M NaOH and 1% CAN, and a step-wise gradient was used to separate the product and starting materials, with specific conditions determined by column capacity. A representative purification gradient is: 7 to 15% B in 5 min, 15 to 17% B in 10 min, 17 to 50% B in 1 min, and 50% B for 9 min (flow rate of 4 mL/min). Elution fractions were collected with the UV-VIS flow-cell lamp turned off to prevent photolysis. Fractions (1 mL) were collected every 15 sec and buffered with aq. 1 M NH 4 OAc, pH 5 (40 µL). Product-containing fractions were identified by absorbance using a Nanodrop spectrophotometer (Thermo Scientific), combined, and lyophilized to dryness. The residue was redissolved in 400 µL of water and passed through a NAP™5 size exclusion column (GE Healthcare).
MS-ESI
Eluent volume was reduced in vacuo to 50 µL and the MOs were precipitated with acetone (400 µL).
After centrifugation, the supernatant was discarded and the MO pellet was washed with CH 3 CN (100 µL) and lyophilized to dryness. cMO 22b was recovered as a white solid (7 nmol, 7% overall). 

